Epizyme's EZH2 blocker boosts immuno-oncology response in prostate cancer models

Retrieved on: 2021-04-19 13:20:31

Tags for this article:

Click the tags to see associated articles and topics

Epizyme's EZH2 blocker boosts immuno-oncology response in prostate cancer models. View article details on hiswai:

Excerpt

Inhibiting EZH2 either genetically or with a chemical inhibitor signaled the immune system to respond to PD-1 inhibition in prostate cancer. (NIH).

Article found on: www.fiercebiotech.com